Vor Biopharma has shifted focus to immunology, raising over $500 million in 2025 to support the US approval process for telitacicept, a drug already approved in China for multiple uses. The company holds $530 million in cash, extending its financial runway to 2029, but investors should be cautious due to potential dilution from outstanding warrants and equity plans. Telitacicept must complete pivotal Phase 3 trials in the US, with data expected by 2027. Given the intense competition and lack of near-term catalysts, the analyst maintains a Hold rating on Vor Biopharma.
Leading Japanese companies, startups, and research institutions are developing specialized AI models using NVIDIA Nemotron open models to address Japan's unique language, industrial, and workforce challenges. These AI applications range from enterpri...
ARCpoint Inc. announced it will likely miss the July 29, 2026 deadline to file its annual financial statements and related reports due to a lack of funds to pay auditors. The company has applied for a Management Cease Trade Order (MCTO) and awaits ap...
Western Star Resources has granted 2 million incentive stock options to its directors, officers, employees, and consultants. These options are exercisable until July 15, 2029, at a price of $0.30 per share. This move aligns with the company's goal to...
Ecopetrol, Colombia's largest energy company, will announce its financial and operating results for the second quarter of 2026 on August 3 after market close. A virtual conference will follow on August 4, featuring simultaneous Spanish and English br...
Galaxy Digital reports that large Bitcoin holders (whales) have not sold their holdings over fears of quantum computing risks. Instead, concerns about quantum threats seem to influence institutional investors who are hesitant to buy Bitcoin. Recent l...
